Kazia Therapeutics and Sovargen Collaborate to Develop Paxalisib for Treating Intractable Seizures in Rare CNS Diseases
Shots:
- Kazia Therapeutics and Sovargen have signed an exclusive licensing agreement for the development, manufacturing & commercialization of paxalisib to treat intractable epilepsy in focal cortical dysplasia type 2 (FCD T2) & tuberous sclerosis complex (TSC) disease
- Under the collaboration, Kazia obtains $1.5M up front, ~$19M as development & regulatory milestones, a percentage of sub-licensing revenues as well as net-sales-based royalties. Kazia holds on to the rights across mainland China, Hong Kong, Macao & Taiwan
- Paxalisib (oral) is a dual inhibitor of PI3K and mTOR having the ability to penetrate the brain and is designed for the treatment of various brain cancer types
Ref: Kazia Therapeutics | Image: Kazia Therapeutics
Related News:- Evotec Signs a License Agreement with Kazia Therapeutics for Clinical Development of EVT801
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
